Steph & Co. Sells 625 Shares of Kenvue Inc. (NYSE:KVUE)

Steph & Co. cut its stake in Kenvue Inc. (NYSE:KVUE) by 2.6% in the 4th quarter, Holdings Channel reports. The firm owned 22,980 shares of the company’s stock after selling 625 shares during the period. Steph & Co.’s holdings in Kenvue were worth $491,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of KVUE. Leo Wealth LLC increased its position in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after buying an additional 481 shares during the period. Alerus Financial NA boosted its position in Kenvue by 0.3% during the 3rd quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after acquiring an additional 491 shares in the last quarter. Massmutual Trust Co. FSB ADV grew its holdings in shares of Kenvue by 6.2% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after acquiring an additional 492 shares during the period. Wolff Wiese Magana LLC grew its holdings in shares of Kenvue by 0.7% during the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after acquiring an additional 501 shares during the period. Finally, Marathon Capital Management raised its position in shares of Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after acquiring an additional 514 shares in the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on KVUE. JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Royal Bank of Canada upgraded shares of Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Jefferies Financial Group began coverage on shares of Kenvue in a research note on Tuesday, September 24th. They issued a “buy” rating and a $27.00 price target for the company. Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Barclays upgraded shares of Kenvue to a “hold” rating in a report on Thursday, December 12th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $23.18.

Kenvue Trading Down 1.0 %

NYSE:KVUE opened at $20.83 on Thursday. The stock has a market cap of $39.94 billion, a price-to-earnings ratio of 37.87, a PEG ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The company’s 50 day moving average price is $22.50 and its 200-day moving average price is $21.64. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $24.46.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to the consensus estimate of $3.92 billion. During the same period last year, the business posted $0.31 EPS. The company’s revenue was down .4% compared to the same quarter last year. On average, equities research analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.